[Anti-HIV chemoprophylaxis for blood-exposure accidents].
Chemoprophylaxis against HIV after accidental blood exposures represents a new indication for antiretroviral drugs. Efficacy has been suggested by the results of a case-control study in health care workers and the reduction of mother to infant transmission of HIV with zidovudine. The post-exposure treatment should be given as soon as possible, and in the latest at 48 hours. National guidelines recommend a triple therapy with or without protease inhibitor, adapted to the source patient. The evaluation of efficacy needs a standardized follow-up.
Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Cl. -Bernard, 46, rue Henri-Huchard, 75877 Paris Cedex 18.
E
E
Bouvet
E
E
Casalino
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004359:Drug Therapy, Combination; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006282:Health Personnel / Q000706:statistics & numerical data; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control / Q000706:statistics & numerical data; D016602:Needlestick Injuries / Q000150:complications* / Q000453:epidemiology; D016273:Occupational Exposure / Q000517:prevention & control / Q000706:statistics & numerical data; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D015215:Zidovudine